{"url_path":"/sec/lona/8-k/2026-06-23/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-23","source_url":"https://www.sec.gov/Archives/edgar/data/1620463/0001193125-26-279425-index.html","accession_number":"0001193125-26-279425","cik":"0001620463","ticker":"LONA","issuer_name":"LeonaBio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1620463/0001193125-26-279425-index.html","primary_entity_key":"0001620463","primary_entity_name":"LeonaBio, Inc."},"word_count":552,"has_tables":true,"body_markdown":"Item 5.07 Submission of Matters to a Vote of Security Holders.\n\n \n\nOn June 22, 2026, LeonaBio, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The Company had 9,393,514 shares of common stock, par value $0.0001 per share (the “common stock”), outstanding on May 1, 2026, the record date for the Annual Meeting. At the Annual Meeting, 7,908,604 shares of the Company’s common stock, or approximately 84.19% of the total shares entitled to vote, were present or represented by proxy, which constituted a quorum for the transaction of business.\n\n \n\nThe following sets forth the final results of the voting at the Annual Meeting, as certified by the independent inspector of elections for the Annual Meeting. The proposals considered at the Annual Meeting are described in more detail in the Company’s definitive proxy statement filed with the United States Securities and Exchange Commission on May 11, 2026 (the “Proxy Statement”).\n\nProposal No. 1 – Election of Class III Directors\n\nThe stockholders elected the three candidates nominated by the Company’s Board of Directors (the “Board”) to serve as directors of the Company until the annual meeting of stockholders to be held in 2029 or until their successors are elected and qualified, or until their earlier death, resignation or removal. The following sets forth the results of the voting with respect to this proposal:\n\n \n\nNominees of the Board\n\nFor\n\nWithhold\n\nBroker Non-Votes\n\nKelly A. Romano\n\n4,722,901\n\n630,132\n\n2,555,571\n\nJames A. Johnson\n\n5,331,531\n\n21,502\n\n2,555,571\n\nNatalie Holles\n\n5,338,727\n\n14,306\n\n2,555,571\n\nProposal No. 2 – Ratification of Appointment of Independent Registered Public Accounting Firm\n\nThe stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026. The following sets forth the results of the voting with respect to this proposal:\n\n \n\nFor\n\nAgainst\n\nAbstain\n\nBroker Non-Votes\n\n7,824,681\n\n10,708\n\n73,215\n\n0\n\nProposal No. 3 – Approval, on an Advisory Basis, of Compensation of Named Executive Officers\n\nThe stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The following sets forth the results of the voting with respect to this proposal:\n\n \n\nFor\n\nAgainst\n\nAbstain\n\nBroker Non-Votes\n\n5,310,614\n\n24,139\n\n18,280\n\n2,555,571\n\nProposal No. 4 – Approval, on an Advisory Basis, of Frequency of Future Stockholder Advisory Votes on Compensation of Named Executive Officers\n\nThe stockholders indicated, on an advisory basis, their preference for every 3 years as the frequency of holding future stockholder advisory votes on the compensation of the Company’s named executive officers. The following sets forth the results of the voting with respect to this proposal:\n\n \n\n1 Year\n\n2 Years\n\n3 Years\n\nAbstain\n\nBroker Non-Votes\n\n \n\n \n\n2,288,358\n\n7,909\n\n3,052,542\n\n4,224\n\n2,555,571\n\nBased on the results of the vote, and consistent with the Board’s recommendation, the Company has determined to hold a non-binding advisory vote regarding the compensation of its named executive officers every 3 years until the next required non-binding advisory vote on the frequency of holding future votes regarding the compensation of the Company’s named executive officers.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nLeonaBio, Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 23, 2026\n\nBy:\n\n/s/ Mark Litton\n\n \n\n \n\n \n\nMark Litton\n\n \n\n \n\n \n\nPresident and Chief Executive Officer"}